ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.

Quote:

Search for Ticker

Free Membership

Search:

DYAX: Dyax Cp - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

DYAX CP (NASD)
DYAX	3.91	0.26	(7.12%)	Vol. 816,339	16:00 ET

Dyax Corp is a biopharmaceutical company that has developed and patented a method that is used to identify a broad range of compounds with potential for the treatment and diagnosis of diseases. The company is also using this method to identify compounds that could be used in purifying andmanufacturing biopharmaceuticals and other chemicals. The company's phage display technology to rapidly and cost-effectively determine the potential medical uses of newly discovered proteins and genes and subsequently discover biopharmaceutical product candidates.

General Information

DYAX CORP

300 Technology Square Cambridge, MA 02139 Phone: 617 225-2500 Fax: 617 225-2501 Web: www.dyax.com Email: ir@dyax.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/24/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	3.65
52 Week High	4.39
52 Week Low	1.55
Beta	1.95
20 Day Moving Average	477,387.50
Target Price Consensus	5.13

% Price Change
4 Week	27.78
12 Week	6.54
YTD	7.42

% Price Change Relative to S&P 500
4 Week	27.96
12 Week	0.64
YTD	-26.70

Share Information
Shares Outstanding (millions)	72.47
Market Capitalization (millions)	283.36
Short Ratio	7.28
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.17
Current Year EPS Consensus Estimate	-0.95
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/24/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.33
30 Days Ago	1.33
60 Days Ago	1.33
90 Days Ago	1.33

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	44.83%
vs. Previous Quarter	30.43%

Sales Growth
vs. Previous Year	-17.89%
vs. Previous Quarter:	6.45%

Price Ratios
Price/Book	-
Price/Cash Flow	-
Price / Sales	6.14

ROE
09/30/09	-
06/30/09	-
03/31/09	-

ROA
09/30/09	-65.62
06/30/09	-66.46
03/31/09	-75.76

Current Ratio
09/30/09	2.12
06/30/09	2.36
03/31/09	2.40

Quick Ratio
09/30/09	2.12
06/30/09	2.36
03/31/09	2.40

Operating Margin
09/30/09	-92.19
06/30/09	-105.33
03/31/09	-127.85

Net Margin
09/30/09	-97.60
06/30/09	-126.18
03/31/09	-149.73

Pre-Tax Margin
09/30/09	-97.60
06/30/09	-126.18
03/31/09	-149.73

Book Value
09/30/09	-0.68
06/30/09	-0.53
03/31/09	-0.66

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	-1.20
06/30/09	-1.56
03/31/09	-1.41

Debt to Capital
09/30/09	-
06/30/09	-
03/31/09	-


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research